Magenkarzinom-Update

Die aktuell publizierte 2. Version der Deutschen S3-Leitlinie zum Magenkarzinom und Adenokarzinom des ösophagogastralen Übergangs umfasst wichtige Neuerungen bei Diagnostik und Staging, in der endoskopischen Resektionstherapie der Magenfrühkarzinome, der Etablierung minimalinvasiver Operationstechniken sowie einen neuen Standard für die neoadjuvante/perioperative Chemotherapie, eine zunehmend individualisierte Therapie bei limitiert metastasierten Karzinomen und die Empfehlung für eine systematische Tumornachsorge. Diese Übersichtsarbeit bezieht sich auf diese aktualisierte S3-Leitlinie [1], [2].

Schlüsselwörter

Magen-Darm-Trakt - Gastrointestinaltrakt - Tumorchirurgie - Ösophaguskarzinom - Magenkrebs

• Literatur

• 1 Mohler M. S3-Leitlinie Magenkarzinom. Z Gastroenterol 2019; 57: 1515-1516
• 2 Monig S, Ott K, Gockel I. et al. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs, Version 2.0-August 2019. AWMF Register Nr. 032/009OL. Chirurg 2020; 91: 37-40
• 3 Berlth F, Chon SH, Chevallay M. et al. Preoperative staging of nodal status in gastric cancer. Transl Gastroenterol Hepatol 2017; 2: 8
• 4 Chevallay M, Jung M, Niclauss N. et al. [Diagnosis and management of gastro-esophageal junction tumor]. Rev Med Suisse 2017; 13: 1236-1239
• 5 Zhao Z, Yin Z, Wang S. et al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol 2016; 31: 1539-1545
• 6 Brierley JD GM, Wittekind C, Amin MB. TNM Classification of malignant Tumours. 8th ed. Oxford: Wiley Blackwell; 2017
• 7 Monig SP, Schroder W, Baldus SE. et al. Preoperative lymph-node staging in gastrointestinal cancer-correlation between size and tumor stage. Onkologie 2002; 25: 342-344
• 8 Monig SP, Zirbes TK, Schroder W. et al. Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol 1999; 173: 365-367
• 9 Mönig SP, Schneider PM. Adenokarzinome des ösophagogastralen Übergangs: primäres Staging. Onkologe 2019; 25: 1065-1072
• 10 Alakus H, Batur M, Schmidt M. et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 2010; 31: 532-538
• 11 Friedel D, Stavropoulos SN. Introduction of endoscopic submucosal dissection in the West. World J Gastrointest Endosc 2018; 10: 225-238
• 12 Facciorusso A, Antonino M, Di Maso M. et al. Endoscopic submucosal dissection vs. endoscopic mucosal resection for early gastric cancer: A meta-analysis. World J Gastrointest Endosc 2014; 6: 555-563
• 13 Probst A, Schneider A, Schaller T. et al. Endoscopic submucosal dissection for early gastric cancer: are expanded resection criteria safe for Western patients?. Endoscopy 2017; 49: 855-865
• 14 Gotoda T, Yanagisawa A, Sasako M. et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219-225
• 15 Abdelfatah MM, Barakat M, Othman MO. et al. The incidence of lymph node metastasis in submucosal early gastric cancer according to the expanded criteria: a systematic review. Surg Endosc 2019; 33: 26-32
• 16 Holscher AH, Drebber U, Monig SP. et al. Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. Ann Surg 2009; 250: 791-797
• 17 Oh SY, Lee KG, Suh YS. et al. Lymph node metastasis in mucosal gastric cancer: reappraisal of expanded indication of endoscopic submucosal dissection. Ann Surg 2017; 265: 137-142
• 18 Coburn N, Cosby R, Klein L. et al. Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treat Rev 2018; 63: 104-115
• 19 Kim BS, Oh ST, Yook JH. et al. Appropriate gastrectomy resection margins for early gastric carcinoma. J Surg Oncol 2014; 109: 198-201
• 20 Siewert JR, Holscher AH, Becker K. et al. Kardiakarzinom: Versuch einer therapeutisch relevanten Klassifikation. Chirurg 1987; 58: 25-32
• 21 Chevallay M, Bollschweiler E, Chandramohan SM. et al. Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Ann NY Acad Sci 2018; 1434: 132-138
• 22 Holscher AH, Gockel I, Porschen R. Aktualisierte S3-Leitlinie zum Ösophaguskarzinom und Ergänzungen aus chirurgischer Sicht. Chirurg 2019; 90: 398-402
• 23 Sasako M, Sano T, Yamamoto S. et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644-651
• 24 Niclauss N, Jung MK, Chevallay M. et al. Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. Updates Surg 2019; 71: 401-409
• 25 Holscher AH, Law S. Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E = G and GE cancers. Gastric Cancer 2020; 23: 3-9
• 26 Monig SP, Collet PH, Baldus SE. et al. Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus. J Surg Oncol 2001; 76: 89-92
• 27 Pasquer A, Renaud F, Hec F. et al. Is centralization needed for esophageal and gastric cancer patients with low operative risk? A nationwide study. Ann Surg 2016; 264: 823-830
• 28 Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137: 511-520
• 29 Killeen SD, OʼSullivan MJ, Coffey JC. et al. Provider volume and outcomes for oncological procedures. Br J Surg 2005; 92: 389-402
• 30 Meyer HJ. The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer. Eur J Surg Oncol 2005; 31: 595-604
• 31 Songun I, Putter H, Kranenbarg EM. et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449
• 32 Kitano S, Iso Y, Moriyama M. et al. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994; 4: 146-148
• 33 Ludwig K, Moller D, Bernhardt J. Chirurgische Strategie bei Frühkarzinomen des Magens. Chirurg 2018; 89: 347-357
• 34 Chevallay M, Jung M, Berlth F. et al. Laparoscopic surgery for gastric cancer: the European point of view. J Oncol 2019; 2019: 8738502
• 35 Memon MA, Khan S, Yunus RM. et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008; 22: 1781-1789
• 36 Deng Y, Zhang Y, Guo TK. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: A meta-analysis based on seven randomized controlled trials. Surg Oncol 2015; 24: 71-77
• 37 Ludwig K, Schneider-Koriath S, Scharlau U. et al. Totally laparoscopic versus open gastrectomy for gastric cancer: a matched pair analysis. Zentralbl Chir 2018; 143: 145-154
• 38 Son T, Lee JH, Kim YM. et al. Robotic spleen-preserving total gastrectomy for gastric cancer: comparison with conventional laparoscopic procedure. Surg Endosc 2014; 28: 2606-2615
• 39 Park JM, Kim HI, Han SU. et al. Who may benefit from robotic gastrectomy? A subgroup analysis of multicenter prospective comparative study data on robotic versus laparoscopic gastrectomy. Eur J Surg Oncol 2016; 42: 1944-1949
• 40 Goetze OT, Al-Batran SE, Chevallay M. et al. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018; 70: 173-179
• 41 Hoeppner J, Lordick F, Brunner T. et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016; 16: 503
• 42 Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957
• 43 van Heijl M, van Lanschot JJ, Koppert LB. et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008; 8: 21
• 44 Mönig SP, van Hootegem S, Chevallay M. et al. The role of surgery in advanced disease for esophageal and junctional cancer. Best Pract Res Clin Gastroenterol 2018; 36 – 37: 91-96
• 45 Al-Batran SE, Homann N, Pauligk C. et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol 2017; 3: 1237-1244
• 46 Al-Batran SE, Goetze TO, Mueller DW. et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 2017; 17: 893
• 47 Fujitani K, Yang HK, Mizusawa J. et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17: 309-318
• 48 Woo JW, Ryu KW, Park JY. et al. Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection. World J Surg 2014; 38: 439-446
• 49 Lordick F, Ott K, Novotny A. et al. R1-Resektion in der Chirurgie des oberen Gastrointestinaltrakts. Bedeutung und therapeutische Konsequenzen. Chirurg 2007; 78: 792-801
• 50 Raziee HR, Cardoso R, Seevaratnam R. et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer 2012; 15 Suppl 1: S116-S124